home / stock / cocp / cocp quote
Last: | $1.5559 |
---|---|
Change Percent: | -1.79% |
Open: | $1.59 |
Close: | $1.5559 |
High: | $1.59 |
Low: | $1.5 |
Volume: | 3,850 |
Last Trade Date Time: | 04/24/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.5559 | $1.59 | $1.5559 | $1.59 | $1.5 | 3,850 | 04-24-2024 |
$1.562 | $1.59 | $1.562 | $1.59 | $1.562 | 741 | 04-23-2024 |
$1.52 | $1.53 | $1.52 | $1.57 | $1.51 | 9,707 | 04-22-2024 |
$1.5299 | $1.545 | $1.5299 | $1.5999 | $1.48 | 7,631 | 04-19-2024 |
$1.495 | $1.47 | $1.495 | $1.495 | $1.4601 | 5,074 | 04-18-2024 |
$1.43 | $1.4726 | $1.43 | $1.5304 | $1.4196 | 8,388 | 04-17-2024 |
$1.46 | $1.4 | $1.46 | $1.5211 | $1.35 | 19,168 | 04-16-2024 |
$1.4079 | $1.45 | $1.4079 | $1.49 | $1.39 | 22,345 | 04-15-2024 |
$1.45 | $1.5568 | $1.45 | $1.5568 | $1.44 | 13,359 | 04-12-2024 |
$1.55 | $1.58 | $1.55 | $1.58 | $1.51 | 7,596 | 04-11-2024 |
$1.5799 | $1.57 | $1.5799 | $1.5996 | $1.5019 | 9,971 | 04-10-2024 |
$1.55 | $1.54 | $1.55 | $1.601 | $1.5184 | 9,641 | 04-09-2024 |
$1.56 | $1.65 | $1.56 | $1.67 | $1.521 | 9,127 | 04-08-2024 |
$1.595 | $1.42 | $1.595 | $1.63 | $1.42 | 60,255 | 04-05-2024 |
$1.47 | $1.43 | $1.47 | $1.5371 | $1.42 | 21,774 | 04-04-2024 |
$1.4338 | $1.48 | $1.4338 | $1.55 | $1.4244 | 8,258 | 04-03-2024 |
$1.48 | $1.51 | $1.48 | $1.5482 | $1.46 | 10,128 | 04-02-2024 |
$1.5 | $1.5 | $1.5 | $1.5516 | $1.4 | 37,784 | 04-01-2024 |
$1.4 | $1.53 | $1.4 | $1.74 | $1.4 | 83,047 | 03-29-2024 |
$1.4 | $1.53 | $1.4 | $1.74 | $1.4 | 83,047 | 03-28-2024 |
News, Short Squeeze, Breakout and More Instantly...
Cocrystal Pharma Inc. Company Name:
COCP Stock Symbol:
NASDAQ Market:
Cocrystal Pharma Inc. Website:
FDA feedback following the Company’s submission of a Pre-IND briefing package improves clarity on regulatory requirements for Phase 2b influenza A clinical trial with oral CC-42344, a broad-spectrum PB2 inhibitor Topline data expected in 2024 from Phase 2a influenza A human challen...
Feedback provides greater clarity on regulatory requirements for planned Phase 2b trial BOTHELL, Wash., March 19, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces it has received Pre-Investigational New D...
LOS ANGELES, CA / ACCESSWIRE / March 5, 2024 / Planet MicroCap today published a new Video Interview with Jim Martin, Co-CEO and CFO, from Cocrystal Pharma, Inc. (NASDAQ:COCP), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replicat...